Home » Intradigm Eyes Cancer for First Clinical Candidate; Will Go It Alone if Necessary

Intradigm Eyes Cancer for First Clinical Candidate; Will Go It Alone if Necessary

May 07, 2004
Premium

Intradigm has found its lead RNAi-based drug candidate in ICS-283, and while the drug’s target — the VEGF pathway — is nothing new in the RNAi field, the company is likely to pursue a novel indication for the compound.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Best Options

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

A Butterfly's Wings

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

This Week in PNAS

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Pathogen Tracking

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.

What's Popular?

In Gene Silencing/Gene Editing

  1. Researchers Track Cancer Mutations Using CRISPR, Organoid Cultures

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.